Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02956499
Other study ID # APX001-101
Secondary ID C4791001
Status Completed
Phase Phase 1
First received
Last updated
Start date May 24, 2016
Est. completion date July 3, 2017

Study information

Verified date May 2024
Source Basilea Pharmaceutica
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

First In Human (FIH), randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) escalation study of approximately 80 subjects. The SAD portion of the study will enroll six cohorts of eight healthy subjects per cohort, for a total of approximately 48 healthy subjects. The MAD portion of the study will enroll four cohorts of eight healthy subjects per cohort, for a total of approximately 32 healthy subjects.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date July 3, 2017
Est. primary completion date July 3, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Women of childbearing potential must agree to avoid pregnancy during the study and to use contraception at least 2 weeks before the start of the study until 3 months after the last dose of study drug. - Males with partner(s) of childbearing potential must agree to use appropriate barrier contraception from the screening period until 3 months after the last dose of study drug. - Screening hematology, clinical chemistry, coagulation and urinalysis consistent with overall good health. - No significantly abnormal findings on physical examination, ECG and vital signs. - Willing and able to provide written informed consent. Exclusion Criteria: - Any uncontrolled or active major systemic disease including, but not limited to: cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with metastatic potential. - History or presence of malignancy within the past year. Subjects who have been successfully treated with no recurrence of basal cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled. - Use of prescription medication within 14 days prior to the first dose of study drug and throughout the study. - Use of non-prescription or over-the-counter medications within 7 days prior to the first dose of study drug and throughout the study. - Positive results on any of the following Screening laboratory tests: serum pregnancy test, urine alcohol test, urine drugs of abuse, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
APX001 single dose 1

APX001 single dose 2

APX001 single dose 3

APX001 single dose 4

APX001 single dose 5

APX001 single dose 6

APX001 multiple dose 1

APX001 multiple dose 2

APX001 multiple dose 3

APX001 multiple dose 4

Matching Placebo


Locations

Country Name City State
Netherlands PRA Health Sciences Groningen
Netherlands PRA Health Sciences Groningen

Sponsors (1)

Lead Sponsor Collaborator
Basilea Pharmaceutica

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of single and multiple doses of APX001 as measured by adverse events (AEs), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG). 21 days
Secondary Pharmacokinetics of single and multiple doses of APX001 as measured by maximum observed concentration (Cmax). 21 days
Secondary Pharmacokinetics of single and multiple doses of APX001 as measured by area under the curve (AUC). 21 days
Secondary Pharmacokinetics of single and multiple doses of APX001 as measured by terminal phase half-life (t1/2). 21 days
Secondary Pharmacokinetics of single and multiple doses of APX001 as measured by volume of distribution (Vd). 21 days
Secondary Pharmacokinetics of single and multiple doses of APX001 as measured by elimination rate constant (Kel). 21 days
Secondary Pharmacokinetics of single and multiple dose of APX001 as measured by accumulation ratio. 21 days
See also
  Status Clinical Trial Phase
Completed NCT03641131 - Ampholipad Real-World Data in Taiwan
Not yet recruiting NCT03292224 - Systemic Fungal Infections in ICU Patients N/A
Completed NCT01371656 - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Phase 3
Completed NCT00936117 - Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Phase 2
Completed NCT00740389 - TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. Phase 1
Completed NCT03857399 - Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin Phase 2
Not yet recruiting NCT04215458 - Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases N/A
Completed NCT03667690 - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Phase 3
Completed NCT02957929 - Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally Phase 1
Completed NCT01419678 - Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients N/A
Recruiting NCT00333645 - Prophylaxis With Caspofungin in High-Risk Liver Transplantation Phase 2
Not yet recruiting NCT03650439 - Fungal Infections in Patients With Hematological Malignancies
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Withdrawn NCT00430469 - Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients Phase 1/Phase 2
Completed NCT00811642 - Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) Phase 3
Terminated NCT00386997 - ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Phase 4
Completed NCT00514358 - Fluconazole Pharmacokinetics in Infants Phase 1
Completed NCT04166669 - A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001 Phase 1
Recruiting NCT05150327 - Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
Completed NCT02387983 - Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) Phase 1